nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—SLC22A5—Niacin—atherosclerosis	0.0956	0.122	CbGbCtD
Lidocaine—CYP3A7—Simvastatin—atherosclerosis	0.0393	0.0502	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0393	0.0502	CbGbCtD
Lidocaine—CYP3A7—Lovastatin—atherosclerosis	0.0384	0.0491	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0384	0.0491	CbGbCtD
Lidocaine—CYP2B6—Simvastatin—atherosclerosis	0.0374	0.0478	CbGbCtD
Lidocaine—CYP3A5—Rosuvastatin—atherosclerosis	0.0317	0.0405	CbGbCtD
Lidocaine—CYP3A5—Simvastatin—atherosclerosis	0.0295	0.0376	CbGbCtD
Lidocaine—CYP3A5—Pravastatin—atherosclerosis	0.0288	0.0368	CbGbCtD
Lidocaine—CYP3A5—Lovastatin—atherosclerosis	0.0288	0.0368	CbGbCtD
Lidocaine—CYP2C8—Simvastatin—atherosclerosis	0.0283	0.0362	CbGbCtD
Lidocaine—CYP2C8—Pravastatin—atherosclerosis	0.0277	0.0354	CbGbCtD
Lidocaine—CYP2C8—Lovastatin—atherosclerosis	0.0277	0.0354	CbGbCtD
Lidocaine—CYP2D6—Niacin—atherosclerosis	0.0229	0.0292	CbGbCtD
Lidocaine—CYP2C9—Rosuvastatin—atherosclerosis	0.0213	0.0271	CbGbCtD
Lidocaine—ABCB1—Ezetimibe—atherosclerosis	0.0206	0.0263	CbGbCtD
Lidocaine—CYP2C9—Simvastatin—atherosclerosis	0.0198	0.0252	CbGbCtD
Lidocaine—CYP2C9—Lovastatin—atherosclerosis	0.0193	0.0247	CbGbCtD
Lidocaine—CYP2C9—Pravastatin—atherosclerosis	0.0193	0.0247	CbGbCtD
Lidocaine—ABCB1—Simvastatin—atherosclerosis	0.0192	0.0245	CbGbCtD
Lidocaine—ABCB1—Pravastatin—atherosclerosis	0.0188	0.024	CbGbCtD
Lidocaine—ABCB1—Lovastatin—atherosclerosis	0.0188	0.024	CbGbCtD
Lidocaine—CYP2D6—Simvastatin—atherosclerosis	0.0181	0.0231	CbGbCtD
Lidocaine—CYP2D6—Lovastatin—atherosclerosis	0.0177	0.0226	CbGbCtD
Lidocaine—CYP2D6—Pravastatin—atherosclerosis	0.0177	0.0226	CbGbCtD
Lidocaine—CYP3A4—Ezetimibe—atherosclerosis	0.0124	0.0158	CbGbCtD
Lidocaine—CYP3A4—Rosuvastatin—atherosclerosis	0.0124	0.0158	CbGbCtD
Lidocaine—CYP3A4—Simvastatin—atherosclerosis	0.0115	0.0147	CbGbCtD
Lidocaine—CYP3A4—Pravastatin—atherosclerosis	0.0112	0.0144	CbGbCtD
Lidocaine—CYP3A4—Lovastatin—atherosclerosis	0.0112	0.0144	CbGbCtD
Lidocaine—Sensation of heat—Niacin—atherosclerosis	0.00806	0.0693	CcSEcCtD
Lidocaine—Application site reaction—Niacin—atherosclerosis	0.00266	0.0229	CcSEcCtD
Lidocaine—Pregnancy—Lovastatin—atherosclerosis	0.00256	0.022	CcSEcCtD
Lidocaine—Pregnancy—Simvastatin—atherosclerosis	0.00239	0.0206	CcSEcCtD
Lidocaine—Redness—Niacin—atherosclerosis	0.00185	0.0159	CcSEcCtD
Lidocaine—Burning sensation—Niacin—atherosclerosis	0.00179	0.0154	CcSEcCtD
Lidocaine—Laryngospasm—Niacin—atherosclerosis	0.00167	0.0144	CcSEcCtD
Lidocaine—Tenderness—Lovastatin—atherosclerosis	0.00166	0.0143	CcSEcCtD
Lidocaine—Feeling hot—Niacin—atherosclerosis	0.00159	0.0137	CcSEcCtD
Lidocaine—Tenderness—Simvastatin—atherosclerosis	0.00156	0.0134	CcSEcCtD
Lidocaine—Numbness—Pravastatin—atherosclerosis	0.00148	0.0127	CcSEcCtD
Lidocaine—Sensory loss—Pravastatin—atherosclerosis	0.00142	0.0122	CcSEcCtD
Lidocaine—Tenderness—Pravastatin—atherosclerosis	0.00141	0.0121	CcSEcCtD
Lidocaine—Muscle twitching—Niacin—atherosclerosis	0.00127	0.0109	CcSEcCtD
Lidocaine—Dermatitis contact—Niacin—atherosclerosis	0.00123	0.0106	CcSEcCtD
Lidocaine—Skin exfoliation—Niacin—atherosclerosis	0.00119	0.0102	CcSEcCtD
Lidocaine—Neuropathy—Pravastatin—atherosclerosis	0.00115	0.00991	CcSEcCtD
Lidocaine—Dermatitis bullous—Niacin—atherosclerosis	0.000946	0.00814	CcSEcCtD
Lidocaine—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.000939	0.00808	CcSEcCtD
Lidocaine—Diplopia—Pravastatin—atherosclerosis	0.000891	0.00766	CcSEcCtD
Lidocaine—Rhinitis—Rosuvastatin—atherosclerosis	0.000862	0.00742	CcSEcCtD
Lidocaine—Urinary retention—Niacin—atherosclerosis	0.00086	0.0074	CcSEcCtD
Lidocaine—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000796	0.00685	CcSEcCtD
Lidocaine—Dysphagia—Niacin—atherosclerosis	0.000782	0.00673	CcSEcCtD
Lidocaine—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00078	0.00671	CcSEcCtD
Lidocaine—Sweating increased—Pravastatin—atherosclerosis	0.00075	0.00645	CcSEcCtD
Lidocaine—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000744	0.0064	CcSEcCtD
Lidocaine—Angioedema—Rosuvastatin—atherosclerosis	0.000684	0.00588	CcSEcCtD
Lidocaine—Stomatitis—Niacin—atherosclerosis	0.000679	0.00585	CcSEcCtD
Lidocaine—Flushing—Lovastatin—atherosclerosis	0.000676	0.00582	CcSEcCtD
Lidocaine—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000673	0.00579	CcSEcCtD
Lidocaine—Flushing—Ezetimibe—atherosclerosis	0.000663	0.00571	CcSEcCtD
Lidocaine—Chills—Lovastatin—atherosclerosis	0.000654	0.00563	CcSEcCtD
Lidocaine—Angiopathy—Ezetimibe—atherosclerosis	0.000648	0.00558	CcSEcCtD
Lidocaine—Immune system disorder—Ezetimibe—atherosclerosis	0.000645	0.00555	CcSEcCtD
Lidocaine—Flushing—Simvastatin—atherosclerosis	0.000632	0.00544	CcSEcCtD
Lidocaine—Haemoglobin—Niacin—atherosclerosis	0.000629	0.00541	CcSEcCtD
Lidocaine—Rhinitis—Niacin—atherosclerosis	0.000627	0.0054	CcSEcCtD
Lidocaine—Haemorrhage—Niacin—atherosclerosis	0.000626	0.00538	CcSEcCtD
Lidocaine—Hypoaesthesia—Niacin—atherosclerosis	0.000623	0.00536	CcSEcCtD
Lidocaine—Erythema—Ezetimibe—atherosclerosis	0.000622	0.00535	CcSEcCtD
Lidocaine—Dysgeusia—Lovastatin—atherosclerosis	0.000621	0.00534	CcSEcCtD
Lidocaine—Rhinitis—Pravastatin—atherosclerosis	0.000618	0.00532	CcSEcCtD
Lidocaine—Confusional state—Rosuvastatin—atherosclerosis	0.000616	0.0053	CcSEcCtD
Lidocaine—Back pain—Lovastatin—atherosclerosis	0.000613	0.00528	CcSEcCtD
Lidocaine—Hypoaesthesia—Pravastatin—atherosclerosis	0.000613	0.00528	CcSEcCtD
Lidocaine—Chills—Simvastatin—atherosclerosis	0.000611	0.00526	CcSEcCtD
Lidocaine—Visual impairment—Niacin—atherosclerosis	0.000603	0.00519	CcSEcCtD
Lidocaine—Back pain—Ezetimibe—atherosclerosis	0.000602	0.00518	CcSEcCtD
Lidocaine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000599	0.00515	CcSEcCtD
Lidocaine—Vision blurred—Lovastatin—atherosclerosis	0.000598	0.00514	CcSEcCtD
Lidocaine—Tremor—Lovastatin—atherosclerosis	0.000594	0.00511	CcSEcCtD
Lidocaine—Visual impairment—Pravastatin—atherosclerosis	0.000594	0.00511	CcSEcCtD
Lidocaine—Erythema—Simvastatin—atherosclerosis	0.000593	0.0051	CcSEcCtD
Lidocaine—Eye disorder—Niacin—atherosclerosis	0.000585	0.00503	CcSEcCtD
Lidocaine—Tinnitus—Niacin—atherosclerosis	0.000583	0.00502	CcSEcCtD
Lidocaine—Dysgeusia—Simvastatin—atherosclerosis	0.000581	0.005	CcSEcCtD
Lidocaine—Flushing—Niacin—atherosclerosis	0.000581	0.005	CcSEcCtD
Lidocaine—Angioedema—Lovastatin—atherosclerosis	0.00058	0.00499	CcSEcCtD
Lidocaine—Tinnitus—Pravastatin—atherosclerosis	0.000574	0.00494	CcSEcCtD
Lidocaine—Flushing—Pravastatin—atherosclerosis	0.000572	0.00492	CcSEcCtD
Lidocaine—Cardiac disorder—Pravastatin—atherosclerosis	0.000572	0.00492	CcSEcCtD
Lidocaine—Angioedema—Ezetimibe—atherosclerosis	0.000568	0.00489	CcSEcCtD
Lidocaine—Angiopathy—Niacin—atherosclerosis	0.000568	0.00489	CcSEcCtD
Lidocaine—Chills—Niacin—atherosclerosis	0.000561	0.00483	CcSEcCtD
Lidocaine—Vision blurred—Simvastatin—atherosclerosis	0.000559	0.00481	CcSEcCtD
Lidocaine—Tremor—Simvastatin—atherosclerosis	0.000556	0.00478	CcSEcCtD
Lidocaine—Chills—Pravastatin—atherosclerosis	0.000553	0.00476	CcSEcCtD
Lidocaine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000548	0.00472	CcSEcCtD
Lidocaine—Erythema—Niacin—atherosclerosis	0.000545	0.00469	CcSEcCtD
Lidocaine—Angioedema—Simvastatin—atherosclerosis	0.000542	0.00466	CcSEcCtD
Lidocaine—Chest pain—Lovastatin—atherosclerosis	0.00054	0.00465	CcSEcCtD
Lidocaine—Anxiety—Lovastatin—atherosclerosis	0.000538	0.00463	CcSEcCtD
Lidocaine—Hypertension—Ezetimibe—atherosclerosis	0.000537	0.00462	CcSEcCtD
Lidocaine—Tension—Niacin—atherosclerosis	0.000535	0.0046	CcSEcCtD
Lidocaine—Chest pain—Ezetimibe—atherosclerosis	0.00053	0.00456	CcSEcCtD
Lidocaine—Nervousness—Niacin—atherosclerosis	0.000529	0.00455	CcSEcCtD
Lidocaine—Tension—Pravastatin—atherosclerosis	0.000526	0.00453	CcSEcCtD
Lidocaine—Dysgeusia—Pravastatin—atherosclerosis	0.000525	0.00452	CcSEcCtD
Lidocaine—Pain—Rosuvastatin—atherosclerosis	0.000522	0.00449	CcSEcCtD
Lidocaine—Confusional state—Lovastatin—atherosclerosis	0.000522	0.00449	CcSEcCtD
Lidocaine—Nervousness—Pravastatin—atherosclerosis	0.000521	0.00448	CcSEcCtD
Lidocaine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000518	0.00445	CcSEcCtD
Lidocaine—Vision blurred—Niacin—atherosclerosis	0.000513	0.00442	CcSEcCtD
Lidocaine—Confusional state—Ezetimibe—atherosclerosis	0.000512	0.00441	CcSEcCtD
Lidocaine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000508	0.00437	CcSEcCtD
Lidocaine—Vision blurred—Pravastatin—atherosclerosis	0.000505	0.00435	CcSEcCtD
Lidocaine—Chest pain—Simvastatin—atherosclerosis	0.000505	0.00435	CcSEcCtD
Lidocaine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000503	0.00433	CcSEcCtD
Lidocaine—Anxiety—Simvastatin—atherosclerosis	0.000503	0.00433	CcSEcCtD
Lidocaine—Tremor—Pravastatin—atherosclerosis	0.000502	0.00432	CcSEcCtD
Lidocaine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000498	0.00428	CcSEcCtD
Lidocaine—Angioedema—Niacin—atherosclerosis	0.000498	0.00428	CcSEcCtD
Lidocaine—Angioedema—Pravastatin—atherosclerosis	0.00049	0.00422	CcSEcCtD
Lidocaine—Confusional state—Simvastatin—atherosclerosis	0.000488	0.0042	CcSEcCtD
Lidocaine—Urticaria—Rosuvastatin—atherosclerosis	0.000485	0.00418	CcSEcCtD
Lidocaine—Oedema—Simvastatin—atherosclerosis	0.000484	0.00417	CcSEcCtD
Lidocaine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000484	0.00417	CcSEcCtD
Lidocaine—Loss of consciousness—Niacin—atherosclerosis	0.000479	0.00412	CcSEcCtD
Lidocaine—Paraesthesia—Lovastatin—atherosclerosis	0.000465	0.004	CcSEcCtD
Lidocaine—Hypertension—Pravastatin—atherosclerosis	0.000463	0.00398	CcSEcCtD
Lidocaine—Dyspnoea—Lovastatin—atherosclerosis	0.000461	0.00397	CcSEcCtD
Lidocaine—Chest pain—Pravastatin—atherosclerosis	0.000457	0.00393	CcSEcCtD
Lidocaine—Paraesthesia—Ezetimibe—atherosclerosis	0.000456	0.00392	CcSEcCtD
Lidocaine—Anxiety—Pravastatin—atherosclerosis	0.000455	0.00392	CcSEcCtD
Lidocaine—Dyspnoea—Ezetimibe—atherosclerosis	0.000453	0.00389	CcSEcCtD
Lidocaine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00045	0.00387	CcSEcCtD
Lidocaine—Oedema—Niacin—atherosclerosis	0.000445	0.00383	CcSEcCtD
Lidocaine—Anaphylactic shock—Niacin—atherosclerosis	0.000445	0.00383	CcSEcCtD
Lidocaine—Pain—Lovastatin—atherosclerosis	0.000443	0.00381	CcSEcCtD
Lidocaine—Confusional state—Pravastatin—atherosclerosis	0.000441	0.0038	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000438	0.00377	CcSEcCtD
Lidocaine—Asthenia—Rosuvastatin—atherosclerosis	0.000438	0.00377	CcSEcCtD
Lidocaine—Oedema—Pravastatin—atherosclerosis	0.000438	0.00377	CcSEcCtD
Lidocaine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000438	0.00377	CcSEcCtD
Lidocaine—Shock—Niacin—atherosclerosis	0.000437	0.00376	CcSEcCtD
Lidocaine—Paraesthesia—Simvastatin—atherosclerosis	0.000435	0.00374	CcSEcCtD
Lidocaine—Pain—Ezetimibe—atherosclerosis	0.000434	0.00374	CcSEcCtD
Lidocaine—Dyspnoea—Simvastatin—atherosclerosis	0.000432	0.00371	CcSEcCtD
Lidocaine—Hyperhidrosis—Niacin—atherosclerosis	0.00043	0.0037	CcSEcCtD
Lidocaine—Feeling abnormal—Lovastatin—atherosclerosis	0.000427	0.00367	CcSEcCtD
Lidocaine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000423	0.00364	CcSEcCtD
Lidocaine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000418	0.0036	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000418	0.0036	CcSEcCtD
Lidocaine—Hypotension—Niacin—atherosclerosis	0.000415	0.00357	CcSEcCtD
Lidocaine—Pain—Simvastatin—atherosclerosis	0.000414	0.00356	CcSEcCtD
Lidocaine—Urticaria—Lovastatin—atherosclerosis	0.000411	0.00354	CcSEcCtD
Lidocaine—Dizziness—Rosuvastatin—atherosclerosis	0.000404	0.00348	CcSEcCtD
Lidocaine—Urticaria—Ezetimibe—atherosclerosis	0.000403	0.00347	CcSEcCtD
Lidocaine—Paraesthesia—Niacin—atherosclerosis	0.000399	0.00344	CcSEcCtD
Lidocaine—Feeling abnormal—Simvastatin—atherosclerosis	0.000399	0.00343	CcSEcCtD
Lidocaine—Dyspnoea—Niacin—atherosclerosis	0.000396	0.00341	CcSEcCtD
Lidocaine—Somnolence—Niacin—atherosclerosis	0.000395	0.0034	CcSEcCtD
Lidocaine—Paraesthesia—Pravastatin—atherosclerosis	0.000393	0.00338	CcSEcCtD
Lidocaine—Dyspnoea—Pravastatin—atherosclerosis	0.00039	0.00336	CcSEcCtD
Lidocaine—Rash—Rosuvastatin—atherosclerosis	0.000385	0.00331	CcSEcCtD
Lidocaine—Dermatitis—Rosuvastatin—atherosclerosis	0.000385	0.00331	CcSEcCtD
Lidocaine—Urticaria—Simvastatin—atherosclerosis	0.000385	0.00331	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000384	0.0033	CcSEcCtD
Lidocaine—Headache—Rosuvastatin—atherosclerosis	0.000383	0.00329	CcSEcCtD
Lidocaine—Hypersensitivity—Lovastatin—atherosclerosis	0.000381	0.00328	CcSEcCtD
Lidocaine—Pain—Niacin—atherosclerosis	0.00038	0.00327	CcSEcCtD
Lidocaine—Pain—Pravastatin—atherosclerosis	0.000374	0.00322	CcSEcCtD
Lidocaine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000374	0.00322	CcSEcCtD
Lidocaine—Asthenia—Lovastatin—atherosclerosis	0.000371	0.0032	CcSEcCtD
Lidocaine—Asthenia—Ezetimibe—atherosclerosis	0.000364	0.00313	CcSEcCtD
Lidocaine—Nausea—Rosuvastatin—atherosclerosis	0.000363	0.00312	CcSEcCtD
Lidocaine—Feeling abnormal—Pravastatin—atherosclerosis	0.000361	0.0031	CcSEcCtD
Lidocaine—Hypersensitivity—Simvastatin—atherosclerosis	0.000357	0.00307	CcSEcCtD
Lidocaine—Urticaria—Niacin—atherosclerosis	0.000353	0.00304	CcSEcCtD
Lidocaine—Urticaria—Pravastatin—atherosclerosis	0.000348	0.00299	CcSEcCtD
Lidocaine—Asthenia—Simvastatin—atherosclerosis	0.000347	0.00299	CcSEcCtD
Lidocaine—Dizziness—Lovastatin—atherosclerosis	0.000342	0.00295	CcSEcCtD
Lidocaine—Dizziness—Ezetimibe—atherosclerosis	0.000336	0.00289	CcSEcCtD
Lidocaine—Vomiting—Lovastatin—atherosclerosis	0.000329	0.00283	CcSEcCtD
Lidocaine—Hypersensitivity—Niacin—atherosclerosis	0.000328	0.00282	CcSEcCtD
Lidocaine—Rash—Lovastatin—atherosclerosis	0.000326	0.00281	CcSEcCtD
Lidocaine—Dermatitis—Lovastatin—atherosclerosis	0.000326	0.00281	CcSEcCtD
Lidocaine—Headache—Lovastatin—atherosclerosis	0.000324	0.00279	CcSEcCtD
Lidocaine—Vomiting—Ezetimibe—atherosclerosis	0.000323	0.00278	CcSEcCtD
Lidocaine—Hypersensitivity—Pravastatin—atherosclerosis	0.000322	0.00278	CcSEcCtD
Lidocaine—Dizziness—Simvastatin—atherosclerosis	0.00032	0.00276	CcSEcCtD
Lidocaine—Rash—Ezetimibe—atherosclerosis	0.00032	0.00275	CcSEcCtD
Lidocaine—Dermatitis—Ezetimibe—atherosclerosis	0.00032	0.00275	CcSEcCtD
Lidocaine—Asthenia—Niacin—atherosclerosis	0.000319	0.00274	CcSEcCtD
Lidocaine—Headache—Ezetimibe—atherosclerosis	0.000318	0.00274	CcSEcCtD
Lidocaine—Asthenia—Pravastatin—atherosclerosis	0.000314	0.0027	CcSEcCtD
Lidocaine—Vomiting—Simvastatin—atherosclerosis	0.000308	0.00265	CcSEcCtD
Lidocaine—Nausea—Lovastatin—atherosclerosis	0.000307	0.00265	CcSEcCtD
Lidocaine—Rash—Simvastatin—atherosclerosis	0.000305	0.00263	CcSEcCtD
Lidocaine—Dermatitis—Simvastatin—atherosclerosis	0.000305	0.00262	CcSEcCtD
Lidocaine—Headache—Simvastatin—atherosclerosis	0.000303	0.00261	CcSEcCtD
Lidocaine—Nausea—Ezetimibe—atherosclerosis	0.000302	0.0026	CcSEcCtD
Lidocaine—Dizziness—Niacin—atherosclerosis	0.000294	0.00253	CcSEcCtD
Lidocaine—Dizziness—Pravastatin—atherosclerosis	0.000289	0.00249	CcSEcCtD
Lidocaine—Nausea—Simvastatin—atherosclerosis	0.000288	0.00247	CcSEcCtD
Lidocaine—Vomiting—Niacin—atherosclerosis	0.000283	0.00243	CcSEcCtD
Lidocaine—Rash—Niacin—atherosclerosis	0.00028	0.00241	CcSEcCtD
Lidocaine—Dermatitis—Niacin—atherosclerosis	0.00028	0.00241	CcSEcCtD
Lidocaine—Headache—Niacin—atherosclerosis	0.000279	0.0024	CcSEcCtD
Lidocaine—Vomiting—Pravastatin—atherosclerosis	0.000278	0.00239	CcSEcCtD
Lidocaine—Rash—Pravastatin—atherosclerosis	0.000276	0.00237	CcSEcCtD
Lidocaine—Dermatitis—Pravastatin—atherosclerosis	0.000276	0.00237	CcSEcCtD
Lidocaine—Headache—Pravastatin—atherosclerosis	0.000274	0.00236	CcSEcCtD
Lidocaine—Nausea—Niacin—atherosclerosis	0.000264	0.00227	CcSEcCtD
Lidocaine—Nausea—Pravastatin—atherosclerosis	0.00026	0.00224	CcSEcCtD
Lidocaine—CYP2B6—Metabolism—APOB—atherosclerosis	8.49e-06	8.42e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AGT—atherosclerosis	8.47e-06	8.41e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SCARB1—atherosclerosis	8.46e-06	8.39e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—APOE—atherosclerosis	8.42e-06	8.36e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	8.4e-06	8.34e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	8.38e-06	8.32e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CAV1—atherosclerosis	8.34e-06	8.28e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—APOA1—atherosclerosis	8.32e-06	8.26e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—LEP—atherosclerosis	8.3e-06	8.24e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APOE—atherosclerosis	8.3e-06	8.24e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOB—atherosclerosis	8.3e-06	8.23e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CG—atherosclerosis	8.29e-06	8.23e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTM1—atherosclerosis	8.26e-06	8.19e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.23e-06	8.17e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—atherosclerosis	8.23e-06	8.17e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CAV1—atherosclerosis	8.23e-06	8.16e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APOA1—atherosclerosis	8.21e-06	8.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL1B—atherosclerosis	8.19e-06	8.12e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—atherosclerosis	8.12e-06	8.06e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	8.11e-06	8.05e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—LPL—atherosclerosis	8.11e-06	8.04e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTM1—atherosclerosis	8.07e-06	8.01e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HMGCR—atherosclerosis	8.06e-06	7.99e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—atherosclerosis	8e-06	7.94e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HMGCR—atherosclerosis	7.99e-06	7.92e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	7.96e-06	7.9e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOA2—atherosclerosis	7.96e-06	7.9e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	7.96e-06	7.9e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALOX15—atherosclerosis	7.96e-06	7.9e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ESR1—atherosclerosis	7.93e-06	7.87e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—LPL—atherosclerosis	7.92e-06	7.86e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GPX1—atherosclerosis	7.91e-06	7.85e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NAMPT—atherosclerosis	7.87e-06	7.81e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ABCG5—atherosclerosis	7.87e-06	7.81e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—INS—atherosclerosis	7.85e-06	7.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—F2—atherosclerosis	7.83e-06	7.77e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	7.82e-06	7.76e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—LIPC—atherosclerosis	7.82e-06	7.76e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOC3—atherosclerosis	7.77e-06	7.71e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GPX1—atherosclerosis	7.73e-06	7.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—LDLR—atherosclerosis	7.73e-06	7.67e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CD36—atherosclerosis	7.7e-06	7.64e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NFKB1—atherosclerosis	7.64e-06	7.58e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ABCA1—atherosclerosis	7.62e-06	7.56e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CG—atherosclerosis	7.6e-06	7.54e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—LPA—atherosclerosis	7.6e-06	7.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—atherosclerosis	7.59e-06	7.53e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CETP—atherosclerosis	7.55e-06	7.49e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CD36—atherosclerosis	7.53e-06	7.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK8—atherosclerosis	7.51e-06	7.45e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—HMOX1—atherosclerosis	7.5e-06	7.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CG—atherosclerosis	7.49e-06	7.44e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—BGN—atherosclerosis	7.36e-06	7.3e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—atherosclerosis	7.34e-06	7.28e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—MTHFR—atherosclerosis	7.3e-06	7.24e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—atherosclerosis	7.29e-06	7.23e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOA5—atherosclerosis	7.28e-06	7.23e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SCARB1—atherosclerosis	7.23e-06	7.17e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.2e-06	7.15e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ALB—atherosclerosis	7.2e-06	7.14e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—INS—atherosclerosis	7.19e-06	7.14e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOB—atherosclerosis	7.19e-06	7.13e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ABCA1—atherosclerosis	7.18e-06	7.12e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—MAPK3—atherosclerosis	7.18e-06	7.12e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARA—atherosclerosis	7.16e-06	7.11e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—MTHFR—atherosclerosis	7.13e-06	7.08e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ABCA1—atherosclerosis	7.12e-06	7.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—INS—atherosclerosis	7.09e-06	7.04e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.04e-06	6.98e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.01e-06	6.96e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARA—atherosclerosis	7e-06	6.94e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTM1—atherosclerosis	6.99e-06	6.94e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCL2—atherosclerosis	6.98e-06	6.92e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AGT—atherosclerosis	6.93e-06	6.88e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—NOS3—atherosclerosis	6.88e-06	6.83e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—LPL—atherosclerosis	6.86e-06	6.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—atherosclerosis	6.86e-06	6.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IGF1—atherosclerosis	6.86e-06	6.81e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.82e-06	6.77e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—APOE—atherosclerosis	6.79e-06	6.74e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AGT—atherosclerosis	6.78e-06	6.73e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.77e-06	6.72e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CAV1—atherosclerosis	6.73e-06	6.68e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—APOA1—atherosclerosis	6.72e-06	6.67e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GPX1—atherosclerosis	6.7e-06	6.64e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOE—atherosclerosis	6.64e-06	6.59e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ALB—atherosclerosis	6.6e-06	6.54e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CAV1—atherosclerosis	6.58e-06	6.53e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOA1—atherosclerosis	6.57e-06	6.51e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK3—atherosclerosis	6.56e-06	6.51e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—HMOX1—atherosclerosis	6.54e-06	6.49e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CD36—atherosclerosis	6.52e-06	6.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SERPINE1—atherosclerosis	6.51e-06	6.46e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—atherosclerosis	6.34e-06	6.29e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—NOS3—atherosclerosis	6.31e-06	6.26e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—atherosclerosis	6.3e-06	6.25e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOB—atherosclerosis	6.26e-06	6.21e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOS3—atherosclerosis	6.22e-06	6.17e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—MTHFR—atherosclerosis	6.18e-06	6.13e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HMOX1—atherosclerosis	6.16e-06	6.11e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.16e-06	6.11e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CG—atherosclerosis	6.13e-06	6.08e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HMOX1—atherosclerosis	6.11e-06	6.06e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTM1—atherosclerosis	6.09e-06	6.04e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ABCA1—atherosclerosis	6.08e-06	6.04e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.07e-06	6.03e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARA—atherosclerosis	6.06e-06	6.02e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MAPK3—atherosclerosis	6.05e-06	6.01e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—LIPC—atherosclerosis	6.04e-06	5.99e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOC3—atherosclerosis	6e-06	5.95e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CG—atherosclerosis	5.99e-06	5.95e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—LPL—atherosclerosis	5.98e-06	5.93e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—LDLR—atherosclerosis	5.96e-06	5.92e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—atherosclerosis	5.92e-06	5.87e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOB—atherosclerosis	5.9e-06	5.86e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—TGFB1—atherosclerosis	5.87e-06	5.83e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AGT—atherosclerosis	5.87e-06	5.83e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOB—atherosclerosis	5.85e-06	5.8e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GPX1—atherosclerosis	5.83e-06	5.79e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CETP—atherosclerosis	5.82e-06	5.78e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—INS—atherosclerosis	5.8e-06	5.76e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—atherosclerosis	5.78e-06	5.74e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—atherosclerosis	5.77e-06	5.73e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOE—atherosclerosis	5.75e-06	5.71e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.74e-06	5.7e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CAV1—atherosclerosis	5.7e-06	5.66e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTM1—atherosclerosis	5.69e-06	5.65e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOA1—atherosclerosis	5.69e-06	5.64e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CD36—atherosclerosis	5.68e-06	5.64e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—INS—atherosclerosis	5.67e-06	5.63e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—LPL—atherosclerosis	5.63e-06	5.59e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—LPL—atherosclerosis	5.59e-06	5.54e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.58e-06	5.53e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—atherosclerosis	5.52e-06	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GPX1—atherosclerosis	5.5e-06	5.45e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GPX1—atherosclerosis	5.45e-06	5.41e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—MTHFR—atherosclerosis	5.38e-06	5.34e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CD36—atherosclerosis	5.35e-06	5.31e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ALB—atherosclerosis	5.32e-06	5.28e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CD36—atherosclerosis	5.31e-06	5.27e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARA—atherosclerosis	5.28e-06	5.24e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.27e-06	5.23e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—atherosclerosis	5.25e-06	5.21e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.22e-06	5.18e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ALB—atherosclerosis	5.2e-06	5.16e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CG—atherosclerosis	5.19e-06	5.15e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AGT—atherosclerosis	5.11e-06	5.08e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NOS3—atherosclerosis	5.09e-06	5.05e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.07e-06	5.03e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—MTHFR—atherosclerosis	5.03e-06	4.99e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOE—atherosclerosis	5.01e-06	4.97e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—atherosclerosis	5.01e-06	4.97e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOB—atherosclerosis	5e-06	4.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—atherosclerosis	4.99e-06	4.95e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARA—atherosclerosis	4.98e-06	4.94e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NOS3—atherosclerosis	4.98e-06	4.94e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CAV1—atherosclerosis	4.97e-06	4.93e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOA1—atherosclerosis	4.95e-06	4.92e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NFKB1—atherosclerosis	4.94e-06	4.9e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARA—atherosclerosis	4.93e-06	4.9e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—INS—atherosclerosis	4.91e-06	4.88e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.86e-06	4.83e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK8—atherosclerosis	4.85e-06	4.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—atherosclerosis	4.84e-06	4.8e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AGT—atherosclerosis	4.82e-06	4.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—atherosclerosis	4.79e-06	4.76e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AGT—atherosclerosis	4.78e-06	4.74e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—LPL—atherosclerosis	4.77e-06	4.74e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—atherosclerosis	4.76e-06	4.72e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOE—atherosclerosis	4.72e-06	4.69e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.69e-06	4.66e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOE—atherosclerosis	4.68e-06	4.65e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CAV1—atherosclerosis	4.68e-06	4.64e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOA1—atherosclerosis	4.67e-06	4.63e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GPX1—atherosclerosis	4.66e-06	4.62e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—atherosclerosis	4.66e-06	4.62e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CAV1—atherosclerosis	4.64e-06	4.6e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOA1—atherosclerosis	4.63e-06	4.59e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—atherosclerosis	4.55e-06	4.52e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CD36—atherosclerosis	4.53e-06	4.5e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.52e-06	4.49e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ALB—atherosclerosis	4.51e-06	4.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—atherosclerosis	4.48e-06	4.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—atherosclerosis	4.44e-06	4.4e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—atherosclerosis	4.43e-06	4.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—atherosclerosis	4.42e-06	4.39e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—atherosclerosis	4.37e-06	4.33e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NOS3—atherosclerosis	4.31e-06	4.28e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.3e-06	4.26e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—INS—atherosclerosis	4.28e-06	4.25e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.26e-06	4.23e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK3—atherosclerosis	4.24e-06	4.21e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	4.23e-06	4.19e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARA—atherosclerosis	4.22e-06	4.18e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—atherosclerosis	4.11e-06	4.08e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TGFB1—atherosclerosis	4.11e-06	4.08e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AGT—atherosclerosis	4.08e-06	4.05e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—atherosclerosis	4.08e-06	4.05e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—atherosclerosis	4.08e-06	4.05e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—INS—atherosclerosis	4.03e-06	4e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.03e-06	4e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOE—atherosclerosis	4e-06	3.97e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—INS—atherosclerosis	4e-06	3.97e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CAV1—atherosclerosis	3.96e-06	3.93e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOA1—atherosclerosis	3.95e-06	3.92e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.94e-06	3.91e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ALB—atherosclerosis	3.92e-06	3.89e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOB—atherosclerosis	3.86e-06	3.83e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NOS3—atherosclerosis	3.75e-06	3.73e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.75e-06	3.72e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALB—atherosclerosis	3.7e-06	3.67e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—LPL—atherosclerosis	3.68e-06	3.66e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALB—atherosclerosis	3.67e-06	3.64e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.61e-06	3.58e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GPX1—atherosclerosis	3.59e-06	3.57e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NOS3—atherosclerosis	3.54e-06	3.51e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NOS3—atherosclerosis	3.51e-06	3.48e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CD36—atherosclerosis	3.5e-06	3.47e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—atherosclerosis	3.48e-06	3.46e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—atherosclerosis	3.43e-06	3.41e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—INS—atherosclerosis	3.42e-06	3.39e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.32e-06	3.29e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARA—atherosclerosis	3.25e-06	3.23e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.24e-06	3.21e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.21e-06	3.18e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—atherosclerosis	3.16e-06	3.14e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AGT—atherosclerosis	3.15e-06	3.13e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALB—atherosclerosis	3.13e-06	3.11e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—atherosclerosis	3.1e-06	3.08e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOE—atherosclerosis	3.09e-06	3.06e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CAV1—atherosclerosis	3.06e-06	3.04e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOA1—atherosclerosis	3.05e-06	3.03e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NOS3—atherosclerosis	3e-06	2.97e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—atherosclerosis	2.9e-06	2.88e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—atherosclerosis	2.86e-06	2.84e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.79e-06	2.77e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.74e-06	2.72e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—atherosclerosis	2.69e-06	2.67e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—INS—atherosclerosis	2.64e-06	2.62e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALB—atherosclerosis	2.42e-06	2.4e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—atherosclerosis	2.34e-06	2.32e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NOS3—atherosclerosis	2.31e-06	2.3e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—atherosclerosis	2.29e-06	2.27e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.12e-06	2.1e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—atherosclerosis	1.98e-06	1.97e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—atherosclerosis	1.73e-06	1.71e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.63e-06	1.61e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—atherosclerosis	1.61e-06	1.6e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—atherosclerosis	1.38e-06	1.37e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—atherosclerosis	1.06e-06	1.06e-05	CbGpPWpGaD
